FDA places partial hold on CTI BioPharma studies

The Food and Drug Administration placed a partial hold on the clinical studies being conducted by CTI BioPharma Corp. Nasdaq: CTIC) for pacritinib. The stock price plunged 60 cents to close at $0.44.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.